Fig 3.

Oncogenomic changes detected by deep-sequence analysis from archival tumor specimens across 28 subjects. Columns represent individual subjects; rows represent selected genes of interest examined for each sample. Subjects who reached the primary efficacy goal of 6 months progression-free survival (PFS) are marked blue; those who did not are marked gold. Subjects censored within their first 6 months of the trial are marked gray. Colored squares mark the presence of somatic alterations detected by sequence analysis. ARID1A mutations were seen in five of 14 tumors with major papillary features; no ARID1A mutations were seen in all other renal cell carcinoma (RCC) variants. For patients with ARID1A mutations, PFS was > 6 months in five of five, and three of the five achieved a partial response.